Alliance Pharma's revenues for the six months to the end of June rose by 104% to £46.4m. It said ex-Sinclair products had made an immediate contribution to the results, in line with expectations and enabling revenues to more than double and there was underlying revenue growth of 6% in the original Alliance portfolio. The group said its largest-selling brand was now the scar reduction product, Kelo-cote, which achieved H1 sales of £4.1m from a widely spread international base. Hydromol, its emollient range, maintained its double digit growth rate, with H1 sales of £3.5ma and MacuShield, its nutritional supplement product for age related macular degeneration (AMD), delivered H1 sales of £2.0m (£1.4m in the five months after we acquired it in February 2015). Half year EBITDA rose by 109% at £13.2m (H1 2015: £6.3m) and half year PBT was up 113% at £11.7m. Basic earnings per share increased to2.04p (H1 2015: 1.65p)and the interim dividend is up 10% at 0.403p (H1 2015: 0.366p). Chairman Andrew Smith said: "Alliance Pharma is a transformed business with sales and profits in the first half of 2016 having doubled from those of 2015. We are already seeing opportunities to exploit our expanded international capabilities. "We were delighted to announce yesterday the signing of an EU licensing and distribution agreement for Diclectin with Duchesnay Inc., which provides the opportunity to launch this product in a further nine EU territories. This agreement highlights the potential of our strengthened European base."
+0.25p (+0.53%)delayed 18:15PM